These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24945780)

  • 1. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
    Langaee TY; Zhu HJ; Wang X; El Rouby N; Markowitz JS; Goldstein JA; Johnson JA
    Pharmacogenet Genomics; 2014 Aug; 24(8):381-6. PubMed ID: 24945780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.
    Scott SA; Martis S; Peter I; Kasai Y; Kornreich R; Desnick RJ
    Pharmacogenomics J; 2012 Aug; 12(4):297-305. PubMed ID: 21358751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
    Holmes MV; Perel P; Shah T; Hingorani AD; Casas JP
    JAMA; 2011 Dec; 306(24):2704-14. PubMed ID: 22203539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
    Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a CYP2C19 genotyping assay for clinical use.
    Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
    Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.
    Sibbing D; Gebhard D; Koch W; Braun S; Stegherr J; Morath T; Von Beckerath N; Mehilli J; Schömig A; Schuster T; Kastrati A
    J Thromb Haemost; 2010 Aug; 8(8):1685-93. PubMed ID: 20492469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing.
    Scott SA; Tan Q; Baber U; Yang Y; Martis S; Bander J; Kornreich R; Hulot JS; Desnick RJ
    J Mol Diagn; 2013 Nov; 15(6):783-9. PubMed ID: 24012947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T; Iwaki T; Umemura K
    Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.
    Minarik M; Kopeckova M; Gassman M; Osmancik P; Benesova L
    Electrophoresis; 2012 Apr; 33(8):1306-10. PubMed ID: 22589111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.